Korean study checks soliris safety in everyday use for rare nerve disease

NCT ID NCT06448715

First seen Jan 10, 2026 · Last updated May 16, 2026 · Updated 18 times

Summary

This study looked at 11 Korean adults with a rare nerve disease called NMOSD who were already taking or starting the drug Soliris. Researchers tracked side effects and how well the drug prevented relapses in normal medical practice. The goal was to confirm the drug's safety and effectiveness outside of controlled trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBSERVATIONAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Goyang-si, South Korea

  • Research Site

    Seoul, South Korea

Conditions

Explore the condition pages connected to this study.